Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

The pharmaceutical industry hopes that with an increase in biosimilars, the insulin supply ... If insulin is not secreted properly or does not function normally, it can lead to diabetes, which ...

ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...

Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress ... including structure, function, purity and potency. The therapeutic equivalence of FYB202 was demonstrated ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Sandoz is one of the largest biosimilars players in the world and we believe it is well-positioned to benefit from the fast pace of growth the market is expected to enjoy over the next decade. Sandoz ...

Early this year, Kamada announced that it expects continued double-digit growth – all while maintaining profitability – for ...

Discover a study that compared the effectiveness of P043 versus omalizumab in managing uncontrolled allergic asthma.

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...